Peter Ordentlich's most recent trade in Syndax Pharmaceuticals Inc was a trade of 17,428 Stock Options (Right to buy) done . Disclosure was reported to the exchange on Feb. 15, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Syndax Pharmaceuticals Inc | Peter Ordentlich | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2023 | 17,428 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Peter Ordentlich | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 15 Feb 2023 | 17,428 | 17,428 (0%) | 0% | 7.2 | 125,482 | Common Stock |
| Syndax Pharmaceuticals Inc | Peter Ordentlich | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.84 per share. | 15 Feb 2023 | 17,428 | 0 (0%) | 0% | 25.8 | 450,404 | Common Stock |
| Syndax Pharmaceuticals Inc | Peter Ordentlich | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.38 per share. | 15 Feb 2023 | 7,572 | 7,572 (0%) | 0% | 6.4 | 48,309 | Common Stock |
| Syndax Pharmaceuticals Inc | Peter Ordentlich | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.84 per share. | 15 Feb 2023 | 7,572 | 0 (0%) | 0% | 25.8 | 195,688 | Common Stock |
| Syndax Pharmaceuticals Inc | Peter Ordentlich | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2023 | 7,572 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Peter Ordentlich | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 90,000 | 90,000 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Peter Ordentlich | Chief Scientific Officer | Other type of transaction at price $ 17.32 per share. | 31 Jan 2023 | 69 | 69 (0%) | 0% | 17.3 | 1,195 | Common Stock |
| Syndax Pharmaceuticals Inc | Peter Ordentlich | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 28.43 per share. | 31 Jan 2023 | 69 | 0 (0%) | 0% | 28.4 | 1,962 | Common Stock |
| Syndax Pharmaceuticals Inc | Peter Ordentlich | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2022 | 17,200 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Peter Ordentlich | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.05 per share. | 01 Dec 2022 | 17,200 | 265 (0%) | 0% | 25.1 | 430,936 | Common Stock |
| Syndax Pharmaceuticals Inc | Peter Ordentlich | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.38 per share. | 01 Dec 2022 | 17,200 | 17,465 (0%) | 0% | 6.4 | 109,736 | Common Stock |
| Syndax Pharmaceuticals Inc | Peter Ordentlich | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2022 | 4,028 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Peter Ordentlich | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.01 per share. | 01 Dec 2022 | 4,028 | 265 (0%) | 0% | 25.0 | 100,746 | Common Stock |
| Syndax Pharmaceuticals Inc | Peter Ordentlich | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.38 per share. | 01 Dec 2022 | 4,028 | 4,293 (0%) | 0% | 6.4 | 25,699 | Common Stock |
| Syndax Pharmaceuticals Inc | Peter Ordentlich | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.35 per share. | 01 Dec 2022 | 3,772 | 4,037 (0%) | 0% | 6.3 | 23,952 | Common Stock |
| Syndax Pharmaceuticals Inc | Peter Ordentlich | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2022 | 3,772 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Peter Ordentlich | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.01 per share. | 01 Dec 2022 | 3,772 | 265 (0%) | 0% | 25.0 | 94,343 | Common Stock |
| Syndax Pharmaceuticals Inc | Peter Ordentlich | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 29 Jul 2022 | 22,846 | 23,111 (0%) | 0% | 6.3 | 144,387 | Common Stock |
| Syndax Pharmaceuticals Inc | Peter Ordentlich | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jul 2022 | 22,846 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Peter Ordentlich | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.04 per share. | 29 Jul 2022 | 22,846 | 265 (0%) | 0% | 25.0 | 571,966 | Common Stock |
| Syndax Pharmaceuticals Inc | Peter Ordentlich | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jul 2022 | 2,154 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Peter Ordentlich | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.04 per share. | 29 Jul 2022 | 2,154 | 265 (0%) | 0% | 25.0 | 53,927 | Common Stock |
| Syndax Pharmaceuticals Inc | Peter Ordentlich | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.35 per share. | 29 Jul 2022 | 2,154 | 2,419 (0%) | 0% | 6.4 | 13,678 | Common Stock |
| Syndax Pharmaceuticals Inc | Peter Ordentlich | Chief Scientific Officer | Other type of transaction at price $ 14.12 per share. | 29 Jul 2022 | 265 | 265 (0%) | 0% | 14.1 | 3,742 | Common Stock |
| Syndax Pharmaceuticals Inc | Peter Ordentlich | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 80,000 | 80,000 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Peter Ordentlich | Chief Scientific Officer | Other type of transaction at price $ 12.39 per share. | 01 Feb 2022 | 1,412 | 1,412 (0%) | 0% | 12.4 | 17,495 | Common Stock |
| Syndax Pharmaceuticals Inc | Peter Ordentlich | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 16.65 per share. | 01 Feb 2022 | 1,412 | 0 (0%) | 0% | 16.7 | 23,510 | Common Stock |
| Syndax Pharmaceuticals Inc | Peter Ordentlich | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Syndax Pharmaceuticals Inc | Peter Ordentlich | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.08 per share. | 23 Nov 2020 | 24,288 | 24,288 (0%) | 0% | 3.1 | 74,807 | Common Stock |
| Syndax Pharmaceuticals Inc | Peter Ordentlich | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Nov 2020 | 24,288 | 0 | - | - | Stock Option (Right to Buy) | |
| Syndax Pharmaceuticals Inc | Peter Ordentlich | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 22.89 per share. | 23 Nov 2020 | 16,334 | 0 (0%) | 0% | 22.9 | 373,924 | Common Stock |
| Syndax Pharmaceuticals Inc | Peter Ordentlich | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 23.58 per share. | 23 Nov 2020 | 7,954 | 16,334 (0%) | 0% | 23.6 | 187,594 | Common Stock |
| Syndax Pharmaceuticals Inc | Peter Ordentlich | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 23.33 per share. | 23 Nov 2020 | 5,684 | 24,288 (0%) | 0% | 23.3 | 132,603 | Common Stock |
| Syndax Pharmaceuticals Inc | Peter Ordentlich | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.08 per share. | 23 Nov 2020 | 5,684 | 29,972 (0%) | 0% | 3.1 | 17,507 | Common Stock |
| Syndax Pharmaceuticals Inc | Peter Ordentlich | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Nov 2020 | 5,684 | 0 | - | - | Stock Option (Right to Buy) |